NNovo Nordisk Read More Novo Signs $1.3 Billion Nanexa Deal for Long-Acting Drugs2026-09-25 (Bloomberg) — Novo Nordisk A/S signed a deal worth as much as €1.165 billion ($1.3 billion) with Sweden’s…
NNovo Nordisk Read More Nanexa and Novo enter into EUR 1.165 billion global license and collaboration agreement for long-acting injectables2026-09-25 The agreement grants Novo a global exclusive license to Nanexa’s proprietary PharmaShell® atomic layer deposition (ALD) drug delivery…